nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—malignant glioma	0.665	1	CbGaD
Rasagiline—CYP1A2—Carmustine—malignant glioma	0.121	1	CbGbCtD
Rasagiline—Facial paralysis—Carmustine—malignant glioma	0.00243	0.0225	CcSEcCtD
Rasagiline—Retinal haemorrhage—Carmustine—malignant glioma	0.00237	0.022	CcSEcCtD
Rasagiline—Hemiplegia—Carmustine—malignant glioma	0.00216	0.0201	CcSEcCtD
Rasagiline—Hemiplegia—Temozolomide—malignant glioma	0.00209	0.0194	CcSEcCtD
Rasagiline—VIIth nerve paralysis—Carmustine—malignant glioma	0.00188	0.0175	CcSEcCtD
Rasagiline—Paranoid reaction—Carmustine—malignant glioma	0.00182	0.0169	CcSEcCtD
Rasagiline—Personality disorder—Carmustine—malignant glioma	0.00179	0.0166	CcSEcCtD
Rasagiline—Pulmonary fibrosis—Carmustine—malignant glioma	0.00176	0.0163	CcSEcCtD
Rasagiline—Pulmonary fibrosis—Temozolomide—malignant glioma	0.0017	0.0158	CcSEcCtD
Rasagiline—Cerebral ischaemia—Temozolomide—malignant glioma	0.00155	0.0143	CcSEcCtD
Rasagiline—Interstitial pneumonia—Temozolomide—malignant glioma	0.00155	0.0143	CcSEcCtD
Rasagiline—Faecal incontinence—Carmustine—malignant glioma	0.00153	0.0142	CcSEcCtD
Rasagiline—Faecal incontinence—Temozolomide—malignant glioma	0.00148	0.0137	CcSEcCtD
Rasagiline—Cerebral haemorrhage—Carmustine—malignant glioma	0.0014	0.0129	CcSEcCtD
Rasagiline—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00135	0.0125	CcSEcCtD
Rasagiline—Myasthenia—Carmustine—malignant glioma	0.00123	0.0114	CcSEcCtD
Rasagiline—Aphasia—Carmustine—malignant glioma	0.00119	0.0111	CcSEcCtD
Rasagiline—Cyst—Carmustine—malignant glioma	0.00116	0.0107	CcSEcCtD
Rasagiline—Parosmia—Temozolomide—malignant glioma	0.00115	0.0107	CcSEcCtD
Rasagiline—Aphasia—Temozolomide—malignant glioma	0.00115	0.0107	CcSEcCtD
Rasagiline—Paranoia—Carmustine—malignant glioma	0.00113	0.0105	CcSEcCtD
Rasagiline—Interstitial lung disease—Carmustine—malignant glioma	0.00109	0.0101	CcSEcCtD
Rasagiline—Interstitial lung disease—Temozolomide—malignant glioma	0.00106	0.00979	CcSEcCtD
Rasagiline—Apathy—Temozolomide—malignant glioma	0.00105	0.0097	CcSEcCtD
Rasagiline—Flat affect—Temozolomide—malignant glioma	0.00104	0.00961	CcSEcCtD
Rasagiline—Stupor—Carmustine—malignant glioma	0.00104	0.0096	CcSEcCtD
Rasagiline—Scotoma—Carmustine—malignant glioma	0.00102	0.00944	CcSEcCtD
Rasagiline—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00101	0.00936	CcSEcCtD
Rasagiline—Scotoma—Temozolomide—malignant glioma	0.000984	0.00912	CcSEcCtD
Rasagiline—Accidental injury—Carmustine—malignant glioma	0.000874	0.0081	CcSEcCtD
Rasagiline—Amenorrhoea—Temozolomide—malignant glioma	0.00085	0.00789	CcSEcCtD
Rasagiline—Drug interaction—Carmustine—malignant glioma	0.000833	0.00773	CcSEcCtD
Rasagiline—Gait disturbance—Carmustine—malignant glioma	0.000792	0.00735	CcSEcCtD
Rasagiline—Coordination abnormal—Carmustine—malignant glioma	0.000787	0.0073	CcSEcCtD
Rasagiline—Neck pain—Carmustine—malignant glioma	0.000782	0.00726	CcSEcCtD
Rasagiline—Gait disturbance—Temozolomide—malignant glioma	0.000765	0.0071	CcSEcCtD
Rasagiline—Coordination abnormal—Temozolomide—malignant glioma	0.000761	0.00706	CcSEcCtD
Rasagiline—Musculoskeletal pain—Temozolomide—malignant glioma	0.000756	0.00701	CcSEcCtD
Rasagiline—Vaginal inflammation—Temozolomide—malignant glioma	0.000747	0.00693	CcSEcCtD
Rasagiline—Depressed level of consciousness—Carmustine—malignant glioma	0.000746	0.00692	CcSEcCtD
Rasagiline—Urinary incontinence—Carmustine—malignant glioma	0.000746	0.00692	CcSEcCtD
Rasagiline—Neuropathy—Carmustine—malignant glioma	0.000726	0.00673	CcSEcCtD
Rasagiline—Depressed level of consciousness—Temozolomide—malignant glioma	0.000721	0.00669	CcSEcCtD
Rasagiline—Urinary incontinence—Temozolomide—malignant glioma	0.000721	0.00669	CcSEcCtD
Rasagiline—Vaginal infection—Temozolomide—malignant glioma	0.000705	0.00654	CcSEcCtD
Rasagiline—Neuropathy—Temozolomide—malignant glioma	0.000701	0.00651	CcSEcCtD
Rasagiline—Neoplasm—Carmustine—malignant glioma	0.000699	0.00648	CcSEcCtD
Rasagiline—Gynaecomastia—Carmustine—malignant glioma	0.000692	0.00641	CcSEcCtD
Rasagiline—Neoplasm—Temozolomide—malignant glioma	0.000675	0.00626	CcSEcCtD
Rasagiline—Phlebitis—Carmustine—malignant glioma	0.000651	0.00604	CcSEcCtD
Rasagiline—Thrombophlebitis—Carmustine—malignant glioma	0.000648	0.00601	CcSEcCtD
Rasagiline—Thrombophlebitis—Temozolomide—malignant glioma	0.000626	0.00581	CcSEcCtD
Rasagiline—Eye pain—Carmustine—malignant glioma	0.000622	0.00576	CcSEcCtD
Rasagiline—Gastroenteritis—Temozolomide—malignant glioma	0.000612	0.00567	CcSEcCtD
Rasagiline—Injury—Carmustine—malignant glioma	0.000611	0.00566	CcSEcCtD
Rasagiline—Vascular purpura—Temozolomide—malignant glioma	0.000606	0.00562	CcSEcCtD
Rasagiline—Deafness—Temozolomide—malignant glioma	0.000606	0.00562	CcSEcCtD
Rasagiline—Eye pain—Temozolomide—malignant glioma	0.000601	0.00557	CcSEcCtD
Rasagiline—Amnesia—Carmustine—malignant glioma	0.000597	0.00554	CcSEcCtD
Rasagiline—Amnesia—Temozolomide—malignant glioma	0.000577	0.00535	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000575	0.00533	CcSEcCtD
Rasagiline—Purpura—Temozolomide—malignant glioma	0.000563	0.00522	CcSEcCtD
Rasagiline—Diplopia—Carmustine—malignant glioma	0.000561	0.0052	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000561	0.0052	CcSEcCtD
Rasagiline—Diplopia—Temozolomide—malignant glioma	0.000542	0.00503	CcSEcCtD
Rasagiline—Face oedema—Carmustine—malignant glioma	0.000542	0.00502	CcSEcCtD
Rasagiline—Affect lability—Temozolomide—malignant glioma	0.000534	0.00495	CcSEcCtD
Rasagiline—Ataxia—Carmustine—malignant glioma	0.000528	0.00489	CcSEcCtD
Rasagiline—Face oedema—Temozolomide—malignant glioma	0.000524	0.00486	CcSEcCtD
Rasagiline—Liver function test abnormal—Carmustine—malignant glioma	0.000518	0.0048	CcSEcCtD
Rasagiline—Mood swings—Temozolomide—malignant glioma	0.000514	0.00476	CcSEcCtD
Rasagiline—Ataxia—Temozolomide—malignant glioma	0.00051	0.00473	CcSEcCtD
Rasagiline—Muscular weakness—Carmustine—malignant glioma	0.000495	0.00459	CcSEcCtD
Rasagiline—Dysphagia—Carmustine—malignant glioma	0.000485	0.0045	CcSEcCtD
Rasagiline—Muscular weakness—Temozolomide—malignant glioma	0.000478	0.00444	CcSEcCtD
Rasagiline—Dysphagia—Temozolomide—malignant glioma	0.000469	0.00435	CcSEcCtD
Rasagiline—Dysuria—Temozolomide—malignant glioma	0.000438	0.00406	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000436	0.00404	CcSEcCtD
Rasagiline—Pollakiuria—Temozolomide—malignant glioma	0.000433	0.00402	CcSEcCtD
Rasagiline—Erectile dysfunction—Temozolomide—malignant glioma	0.000432	0.004	CcSEcCtD
Rasagiline—Depression—Carmustine—malignant glioma	0.000431	0.004	CcSEcCtD
Rasagiline—Photosensitivity reaction—Temozolomide—malignant glioma	0.000428	0.00397	CcSEcCtD
Rasagiline—Weight decreased—Temozolomide—malignant glioma	0.000424	0.00393	CcSEcCtD
Rasagiline—Neuropathy peripheral—Carmustine—malignant glioma	0.000424	0.00393	CcSEcCtD
Rasagiline—Stomatitis—Carmustine—malignant glioma	0.000422	0.00391	CcSEcCtD
Rasagiline—Infestation NOS—Temozolomide—malignant glioma	0.000418	0.00388	CcSEcCtD
Rasagiline—Infestation—Temozolomide—malignant glioma	0.000418	0.00388	CcSEcCtD
Rasagiline—Depression—Temozolomide—malignant glioma	0.000417	0.00386	CcSEcCtD
Rasagiline—Neuropathy peripheral—Temozolomide—malignant glioma	0.00041	0.0038	CcSEcCtD
Rasagiline—Stomatitis—Temozolomide—malignant glioma	0.000407	0.00378	CcSEcCtD
Rasagiline—Haemoglobin—Carmustine—malignant glioma	0.00039	0.00362	CcSEcCtD
Rasagiline—Haemorrhage—Carmustine—malignant glioma	0.000388	0.0036	CcSEcCtD
Rasagiline—Hallucination—Carmustine—malignant glioma	0.000386	0.00358	CcSEcCtD
Rasagiline—Hypoaesthesia—Carmustine—malignant glioma	0.000386	0.00358	CcSEcCtD
Rasagiline—Oedema peripheral—Carmustine—malignant glioma	0.000382	0.00355	CcSEcCtD
Rasagiline—Connective tissue disorder—Carmustine—malignant glioma	0.000381	0.00354	CcSEcCtD
Rasagiline—Haemoglobin—Temozolomide—malignant glioma	0.000377	0.0035	CcSEcCtD
Rasagiline—Haemorrhage—Temozolomide—malignant glioma	0.000375	0.00348	CcSEcCtD
Rasagiline—Hallucination—Temozolomide—malignant glioma	0.000373	0.00346	CcSEcCtD
Rasagiline—Hypoaesthesia—Temozolomide—malignant glioma	0.000373	0.00346	CcSEcCtD
Rasagiline—Urinary tract disorder—Temozolomide—malignant glioma	0.00037	0.00344	CcSEcCtD
Rasagiline—Oedema peripheral—Temozolomide—malignant glioma	0.00037	0.00343	CcSEcCtD
Rasagiline—Connective tissue disorder—Temozolomide—malignant glioma	0.000369	0.00342	CcSEcCtD
Rasagiline—Urethral disorder—Temozolomide—malignant glioma	0.000368	0.00341	CcSEcCtD
Rasagiline—Eye disorder—Carmustine—malignant glioma	0.000363	0.00336	CcSEcCtD
Rasagiline—Eye disorder—Temozolomide—malignant glioma	0.000351	0.00325	CcSEcCtD
Rasagiline—Cardiac disorder—Temozolomide—malignant glioma	0.000348	0.00323	CcSEcCtD
Rasagiline—Alopecia—Carmustine—malignant glioma	0.000343	0.00318	CcSEcCtD
Rasagiline—Angiopathy—Temozolomide—malignant glioma	0.00034	0.00316	CcSEcCtD
Rasagiline—Mental disorder—Carmustine—malignant glioma	0.00034	0.00315	CcSEcCtD
Rasagiline—Immune system disorder—Temozolomide—malignant glioma	0.000339	0.00314	CcSEcCtD
Rasagiline—Mediastinal disorder—Temozolomide—malignant glioma	0.000338	0.00314	CcSEcCtD
Rasagiline—Malnutrition—Carmustine—malignant glioma	0.000338	0.00313	CcSEcCtD
Rasagiline—Chills—Temozolomide—malignant glioma	0.000337	0.00312	CcSEcCtD
Rasagiline—Alopecia—Temozolomide—malignant glioma	0.000332	0.00307	CcSEcCtD
Rasagiline—Mental disorder—Temozolomide—malignant glioma	0.000329	0.00305	CcSEcCtD
Rasagiline—Back pain—Carmustine—malignant glioma	0.000327	0.00303	CcSEcCtD
Rasagiline—Malnutrition—Temozolomide—malignant glioma	0.000327	0.00303	CcSEcCtD
Rasagiline—Dysgeusia—Temozolomide—malignant glioma	0.00032	0.00297	CcSEcCtD
Rasagiline—Tremor—Carmustine—malignant glioma	0.000317	0.00294	CcSEcCtD
Rasagiline—Back pain—Temozolomide—malignant glioma	0.000316	0.00293	CcSEcCtD
Rasagiline—Anaemia—Carmustine—malignant glioma	0.000312	0.0029	CcSEcCtD
Rasagiline—Agitation—Carmustine—malignant glioma	0.000311	0.00288	CcSEcCtD
Rasagiline—Tremor—Temozolomide—malignant glioma	0.000306	0.00284	CcSEcCtD
Rasagiline—Ill-defined disorder—Temozolomide—malignant glioma	0.000303	0.00281	CcSEcCtD
Rasagiline—Leukopenia—Carmustine—malignant glioma	0.000302	0.00281	CcSEcCtD
Rasagiline—Anaemia—Temozolomide—malignant glioma	0.000302	0.0028	CcSEcCtD
Rasagiline—Agitation—Temozolomide—malignant glioma	0.0003	0.00278	CcSEcCtD
Rasagiline—Malaise—Temozolomide—malignant glioma	0.000295	0.00273	CcSEcCtD
Rasagiline—Vertigo—Temozolomide—malignant glioma	0.000293	0.00272	CcSEcCtD
Rasagiline—Convulsion—Carmustine—malignant glioma	0.000293	0.00272	CcSEcCtD
Rasagiline—Leukopenia—Temozolomide—malignant glioma	0.000292	0.00271	CcSEcCtD
Rasagiline—Hypertension—Carmustine—malignant glioma	0.000292	0.00271	CcSEcCtD
Rasagiline—Chest pain—Carmustine—malignant glioma	0.000288	0.00267	CcSEcCtD
Rasagiline—Anxiety—Carmustine—malignant glioma	0.000287	0.00266	CcSEcCtD
Rasagiline—Cough—Temozolomide—malignant glioma	0.000285	0.00264	CcSEcCtD
Rasagiline—Convulsion—Temozolomide—malignant glioma	0.000283	0.00262	CcSEcCtD
Rasagiline—Hypertension—Temozolomide—malignant glioma	0.000282	0.00261	CcSEcCtD
Rasagiline—Confusional state—Carmustine—malignant glioma	0.000278	0.00258	CcSEcCtD
Rasagiline—Arthralgia—Temozolomide—malignant glioma	0.000278	0.00258	CcSEcCtD
Rasagiline—Anxiety—Temozolomide—malignant glioma	0.000277	0.00257	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000276	0.00256	CcSEcCtD
Rasagiline—Discomfort—Temozolomide—malignant glioma	0.000275	0.00255	CcSEcCtD
Rasagiline—Infection—Carmustine—malignant glioma	0.000274	0.00254	CcSEcCtD
Rasagiline—Dry mouth—Temozolomide—malignant glioma	0.000272	0.00252	CcSEcCtD
Rasagiline—Confusional state—Temozolomide—malignant glioma	0.000269	0.00249	CcSEcCtD
Rasagiline—Infection—Temozolomide—malignant glioma	0.000265	0.00246	CcSEcCtD
Rasagiline—Anorexia—Carmustine—malignant glioma	0.000263	0.00244	CcSEcCtD
Rasagiline—Nervous system disorder—Temozolomide—malignant glioma	0.000261	0.00242	CcSEcCtD
Rasagiline—Skin disorder—Temozolomide—malignant glioma	0.000259	0.0024	CcSEcCtD
Rasagiline—Hypotension—Carmustine—malignant glioma	0.000258	0.00239	CcSEcCtD
Rasagiline—Hyperhidrosis—Temozolomide—malignant glioma	0.000258	0.00239	CcSEcCtD
Rasagiline—Anorexia—Temozolomide—malignant glioma	0.000254	0.00236	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000251	0.00233	CcSEcCtD
Rasagiline—Insomnia—Carmustine—malignant glioma	0.000249	0.00231	CcSEcCtD
Rasagiline—Paraesthesia—Carmustine—malignant glioma	0.000248	0.0023	CcSEcCtD
Rasagiline—Dyspnoea—Carmustine—malignant glioma	0.000246	0.00228	CcSEcCtD
Rasagiline—Somnolence—Carmustine—malignant glioma	0.000245	0.00227	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000243	0.00225	CcSEcCtD
Rasagiline—Insomnia—Temozolomide—malignant glioma	0.000241	0.00224	CcSEcCtD
Rasagiline—Decreased appetite—Carmustine—malignant glioma	0.00024	0.00222	CcSEcCtD
Rasagiline—Paraesthesia—Temozolomide—malignant glioma	0.000239	0.00222	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Carmustine—malignant glioma	0.000238	0.00221	CcSEcCtD
Rasagiline—Dyspnoea—Temozolomide—malignant glioma	0.000238	0.0022	CcSEcCtD
Rasagiline—Somnolence—Temozolomide—malignant glioma	0.000237	0.0022	CcSEcCtD
Rasagiline—Constipation—Carmustine—malignant glioma	0.000236	0.00219	CcSEcCtD
Rasagiline—Dyspepsia—Temozolomide—malignant glioma	0.000235	0.00218	CcSEcCtD
Rasagiline—Decreased appetite—Temozolomide—malignant glioma	0.000232	0.00215	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00023	0.00213	CcSEcCtD
Rasagiline—Constipation—Temozolomide—malignant glioma	0.000228	0.00211	CcSEcCtD
Rasagiline—Feeling abnormal—Carmustine—malignant glioma	0.000227	0.00211	CcSEcCtD
Rasagiline—Gastrointestinal pain—Carmustine—malignant glioma	0.000226	0.00209	CcSEcCtD
Rasagiline—Feeling abnormal—Temozolomide—malignant glioma	0.00022	0.00204	CcSEcCtD
Rasagiline—Abdominal pain—Carmustine—malignant glioma	0.000218	0.00202	CcSEcCtD
Rasagiline—Body temperature increased—Carmustine—malignant glioma	0.000218	0.00202	CcSEcCtD
Rasagiline—Gastrointestinal pain—Temozolomide—malignant glioma	0.000218	0.00202	CcSEcCtD
Rasagiline—Urticaria—Temozolomide—malignant glioma	0.000212	0.00196	CcSEcCtD
Rasagiline—Body temperature increased—Temozolomide—malignant glioma	0.000211	0.00195	CcSEcCtD
Rasagiline—Abdominal pain—Temozolomide—malignant glioma	0.000211	0.00195	CcSEcCtD
Rasagiline—Hypersensitivity—Carmustine—malignant glioma	0.000203	0.00188	CcSEcCtD
Rasagiline—Asthenia—Carmustine—malignant glioma	0.000198	0.00184	CcSEcCtD
Rasagiline—Hypersensitivity—Temozolomide—malignant glioma	0.000196	0.00182	CcSEcCtD
Rasagiline—Asthenia—Temozolomide—malignant glioma	0.000191	0.00177	CcSEcCtD
Rasagiline—Diarrhoea—Carmustine—malignant glioma	0.000189	0.00175	CcSEcCtD
Rasagiline—Pruritus—Temozolomide—malignant glioma	0.000189	0.00175	CcSEcCtD
Rasagiline—Dizziness—Carmustine—malignant glioma	0.000182	0.00169	CcSEcCtD
Rasagiline—Diarrhoea—Temozolomide—malignant glioma	0.000182	0.00169	CcSEcCtD
Rasagiline—Dizziness—Temozolomide—malignant glioma	0.000176	0.00163	CcSEcCtD
Rasagiline—Vomiting—Carmustine—malignant glioma	0.000175	0.00163	CcSEcCtD
Rasagiline—Rash—Carmustine—malignant glioma	0.000174	0.00161	CcSEcCtD
Rasagiline—Dermatitis—Carmustine—malignant glioma	0.000174	0.00161	CcSEcCtD
Rasagiline—Headache—Carmustine—malignant glioma	0.000173	0.0016	CcSEcCtD
Rasagiline—Vomiting—Temozolomide—malignant glioma	0.000169	0.00157	CcSEcCtD
Rasagiline—Rash—Temozolomide—malignant glioma	0.000168	0.00156	CcSEcCtD
Rasagiline—Dermatitis—Temozolomide—malignant glioma	0.000168	0.00156	CcSEcCtD
Rasagiline—Headache—Temozolomide—malignant glioma	0.000167	0.00155	CcSEcCtD
Rasagiline—Nausea—Carmustine—malignant glioma	0.000164	0.00152	CcSEcCtD
Rasagiline—Nausea—Temozolomide—malignant glioma	0.000158	0.00147	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CASP3—malignant glioma	0.000152	0.00142	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	0.000152	0.00142	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—malignant glioma	0.000151	0.00142	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MDM2—malignant glioma	0.000151	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—RAF1—malignant glioma	0.000151	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CASP3—malignant glioma	0.00015	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—malignant glioma	0.00015	0.0014	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—SPP1—malignant glioma	0.00015	0.0014	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BAD—malignant glioma	0.000148	0.00139	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—AKT1—malignant glioma	0.000147	0.00137	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—AKT1—malignant glioma	0.000147	0.00137	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MDM2—malignant glioma	0.000147	0.00137	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—BAD—malignant glioma	0.000145	0.00136	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—ERBB2—malignant glioma	0.000145	0.00135	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—STAT3—malignant glioma	0.000144	0.00135	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CB—malignant glioma	0.000143	0.00134	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—malignant glioma	0.000141	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—APC—malignant glioma	0.000141	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PDGFB—malignant glioma	0.000138	0.00129	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	0.000137	0.00128	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—AKT1—malignant glioma	0.000137	0.00128	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL1B—malignant glioma	0.000136	0.00127	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MMP2—malignant glioma	0.000135	0.00126	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BRAF—malignant glioma	0.000135	0.00126	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—AKT1—malignant glioma	0.000135	0.00126	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CAV1—malignant glioma	0.000131	0.00123	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—malignant glioma	0.000131	0.00122	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—KDR—malignant glioma	0.00013	0.00121	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT2—malignant glioma	0.000129	0.0012	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—malignant glioma	0.000127	0.00119	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—MET—malignant glioma	0.000127	0.00119	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—malignant glioma	0.000126	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—malignant glioma	0.000126	0.00118	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CAT—malignant glioma	0.000126	0.00118	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—FN1—malignant glioma	0.000125	0.00117	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—malignant glioma	0.000123	0.00115	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—BAD—malignant glioma	0.000123	0.00115	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	0.000123	0.00115	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—MDM2—malignant glioma	0.00012	0.00112	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—malignant glioma	0.00012	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CG—malignant glioma	0.000119	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—AKT1—malignant glioma	0.000119	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	0.000119	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—LGALS3—malignant glioma	0.000118	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGF—malignant glioma	0.000118	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—malignant glioma	0.000118	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	0.000118	0.0011	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—malignant glioma	0.000117	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—AKT1—malignant glioma	0.000116	0.00109	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	0.000115	0.00108	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—COX8A—malignant glioma	0.000113	0.00106	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MDM2—malignant glioma	0.000113	0.00106	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—BRAF—malignant glioma	0.000112	0.00105	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTT1—malignant glioma	0.000111	0.00104	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—AKT2—malignant glioma	0.000109	0.00102	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	0.000109	0.00102	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HLA-C—malignant glioma	0.000106	0.000995	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CD—malignant glioma	0.000105	0.000982	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—malignant glioma	0.000104	0.00097	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL7—malignant glioma	0.000103	0.000963	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—malignant glioma	0.000103	0.000959	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CASP3—malignant glioma	0.000101	0.000947	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—malignant glioma	0.000101	0.000945	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	0.0001	0.000937	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CASP3—malignant glioma	9.91e-05	0.000927	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CTSB—malignant glioma	9.88e-05	0.000924	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—malignant glioma	9.73e-05	0.00091	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ASMT—malignant glioma	9.64e-05	0.000901	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—malignant glioma	9.51e-05	0.000889	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—malignant glioma	9.47e-05	0.000886	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—RAF1—malignant glioma	9.38e-05	0.000877	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	9.37e-05	0.000876	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	9.34e-05	0.000873	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP2B6—malignant glioma	9.29e-05	0.000869	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ERBB2—malignant glioma	9.28e-05	0.000868	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	9.24e-05	0.000864	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—DUSP6—malignant glioma	9.2e-05	0.000861	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP2B6—malignant glioma	9.16e-05	0.000857	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CB—malignant glioma	9.15e-05	0.000856	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—BCAN—malignant glioma	9.06e-05	0.000848	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	9.03e-05	0.000845	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CFH—malignant glioma	9.03e-05	0.000844	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—malignant glioma	8.76e-05	0.000819	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—malignant glioma	8.7e-05	0.000814	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—malignant glioma	8.68e-05	0.000812	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—VEGFA—malignant glioma	8.59e-05	0.000803	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—malignant glioma	8.42e-05	0.000788	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	8.38e-05	0.000784	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EGFR—malignant glioma	8.21e-05	0.000768	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—AKT1—malignant glioma	8.14e-05	0.000762	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP2C18—malignant glioma	8.06e-05	0.000754	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP2C18—malignant glioma	7.95e-05	0.000743	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PTEN—malignant glioma	7.91e-05	0.00074	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—malignant glioma	7.9e-05	0.000739	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	7.88e-05	0.000737	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA2—malignant glioma	7.78e-05	0.000728	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—malignant glioma	7.73e-05	0.000723	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTP1—malignant glioma	7.72e-05	0.000722	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—IDH2—malignant glioma	7.3e-05	0.000683	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—malignant glioma	7.3e-05	0.000683	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—malignant glioma	7.21e-05	0.000674	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—VEGFA—malignant glioma	7.14e-05	0.000668	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	7.11e-05	0.000666	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—AKT1—malignant glioma	7.11e-05	0.000665	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—malignant glioma	7.01e-05	0.000656	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—MDM2—malignant glioma	6.97e-05	0.000652	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—malignant glioma	6.95e-05	0.00065	CbGpPWpGaD
Rasagiline—BCL2—Immune System—LGALS3—malignant glioma	6.9e-05	0.000645	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PARK2—malignant glioma	6.9e-05	0.000645	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—malignant glioma	6.89e-05	0.000645	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2B6—malignant glioma	6.87e-05	0.000642	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTK2—malignant glioma	6.77e-05	0.000634	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—malignant glioma	6.72e-05	0.000629	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	6.55e-05	0.000612	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTT1—malignant glioma	6.52e-05	0.00061	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—malignant glioma	6.49e-05	0.000607	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGFR—malignant glioma	6.43e-05	0.000601	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	6.4e-05	0.000599	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—malignant glioma	6.35e-05	0.000594	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PDGFRA—malignant glioma	6.34e-05	0.000593	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HLA-B—malignant glioma	6.29e-05	0.000589	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—malignant glioma	6.29e-05	0.000588	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—IDH1—malignant glioma	6.28e-05	0.000587	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—malignant glioma	6.25e-05	0.000585	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—malignant glioma	6.23e-05	0.000583	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-C—malignant glioma	6.2e-05	0.00058	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PML—malignant glioma	6.2e-05	0.00058	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—PTGS1—malignant glioma	6.11e-05	0.000571	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	6.1e-05	0.00057	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SPHK1—malignant glioma	6.08e-05	0.000568	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	6.05e-05	0.000566	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2C18—malignant glioma	5.95e-05	0.000557	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTSB—malignant glioma	5.76e-05	0.000538	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PDGFB—malignant glioma	5.69e-05	0.000532	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FGFR1—malignant glioma	5.66e-05	0.00053	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—malignant glioma	5.58e-05	0.000522	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	5.56e-05	0.00052	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—AKT1—malignant glioma	5.48e-05	0.000512	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	5.38e-05	0.000503	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—AKT1—malignant glioma	5.37e-05	0.000502	CbGpPWpGaD
Rasagiline—BCL2—Immune System—DUSP6—malignant glioma	5.36e-05	0.000501	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—malignant glioma	5.29e-05	0.000495	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FBXW7—malignant glioma	5.18e-05	0.000485	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—BAD—malignant glioma	5.07e-05	0.000475	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD80—malignant glioma	4.92e-05	0.00046	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—malignant glioma	4.87e-05	0.000456	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGF—malignant glioma	4.86e-05	0.000454	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTPN11—malignant glioma	4.83e-05	0.000451	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTT1—malignant glioma	4.81e-05	0.00045	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—malignant glioma	4.76e-05	0.000446	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—malignant glioma	4.76e-05	0.000446	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RTEL1—malignant glioma	4.57e-05	0.000427	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—AKT1—malignant glioma	4.56e-05	0.000426	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	4.54e-05	0.000425	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—malignant glioma	4.54e-05	0.000424	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—malignant glioma	4.54e-05	0.000424	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA2—malignant glioma	4.53e-05	0.000424	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—malignant glioma	4.52e-05	0.000422	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS1—malignant glioma	4.51e-05	0.000422	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—malignant glioma	4.5e-05	0.000421	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT2—malignant glioma	4.49e-05	0.00042	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—malignant glioma	4.45e-05	0.000417	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CD—malignant glioma	4.32e-05	0.000404	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—BCHE—malignant glioma	4.19e-05	0.000392	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC5A5—malignant glioma	4.14e-05	0.000388	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FGF2—malignant glioma	4.13e-05	0.000387	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTK2—malignant glioma	3.95e-05	0.000369	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MDM2—malignant glioma	3.87e-05	0.000362	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—RAF1—malignant glioma	3.86e-05	0.000361	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ERBB2—malignant glioma	3.81e-05	0.000357	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CB—malignant glioma	3.76e-05	0.000352	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDGFRA—malignant glioma	3.69e-05	0.000345	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-B—malignant glioma	3.67e-05	0.000343	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-A—malignant glioma	3.4e-05	0.000318	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTP1—malignant glioma	3.34e-05	0.000312	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDGFB—malignant glioma	3.31e-05	0.00031	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGFR1—malignant glioma	3.3e-05	0.000308	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—malignant glioma	3.26e-05	0.000305	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTEN—malignant glioma	3.25e-05	0.000304	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CAT—malignant glioma	3.25e-05	0.000304	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SPHK1—malignant glioma	3.16e-05	0.000295	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOR1—malignant glioma	3.07e-05	0.000287	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BAD—malignant glioma	2.95e-05	0.000276	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD80—malignant glioma	2.87e-05	0.000268	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGF—malignant glioma	2.83e-05	0.000265	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTPN11—malignant glioma	2.81e-05	0.000263	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—malignant glioma	2.64e-05	0.000247	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—COX8A—malignant glioma	2.62e-05	0.000245	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT2—malignant glioma	2.62e-05	0.000245	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CD—malignant glioma	2.52e-05	0.000235	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CAV1—malignant glioma	2.5e-05	0.000234	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—KRAS—malignant glioma	2.5e-05	0.000234	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FGF2—malignant glioma	2.41e-05	0.000225	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—malignant glioma	2.34e-05	0.000219	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—malignant glioma	2.29e-05	0.000215	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CG—malignant glioma	2.28e-05	0.000213	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNG—malignant glioma	2.27e-05	0.000212	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MDM2—malignant glioma	2.25e-05	0.000211	CbGpPWpGaD
Rasagiline—BCL2—Immune System—RAF1—malignant glioma	2.25e-05	0.00021	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ASMT—malignant glioma	2.23e-05	0.000209	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—malignant glioma	2.22e-05	0.000208	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—malignant glioma	2.2e-05	0.000206	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CB—malignant glioma	2.19e-05	0.000205	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—malignant glioma	2.18e-05	0.000204	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BCAN—malignant glioma	2.1e-05	0.000196	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1B—malignant glioma	2.02e-05	0.000189	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—malignant glioma	2.01e-05	0.000188	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CD—malignant glioma	2e-05	0.000187	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—malignant glioma	1.89e-05	0.000177	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—AKT1—malignant glioma	1.87e-05	0.000175	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CB—malignant glioma	1.74e-05	0.000163	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—malignant glioma	1.73e-05	0.000162	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—malignant glioma	1.69e-05	0.000158	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—IDH2—malignant glioma	1.69e-05	0.000158	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.59e-05	0.000149	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2B6—malignant glioma	1.59e-05	0.000149	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—malignant glioma	1.54e-05	0.000144	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—malignant glioma	1.51e-05	0.000141	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—malignant glioma	1.45e-05	0.000136	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—IDH1—malignant glioma	1.45e-05	0.000136	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SPHK1—malignant glioma	1.41e-05	0.000132	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2C18—malignant glioma	1.38e-05	0.000129	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—malignant glioma	1.34e-05	0.000125	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.3e-05	0.000122	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.18e-05	0.000111	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.14e-05	0.000107	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—malignant glioma	1.11e-05	0.000104	CbGpPWpGaD
Rasagiline—BCL2—Immune System—AKT1—malignant glioma	1.09e-05	0.000102	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—malignant glioma	1.06e-05	9.95e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS1—malignant glioma	1.04e-05	9.77e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.04e-05	9.73e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BCHE—malignant glioma	9.71e-06	9.08e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC5A5—malignant glioma	9.59e-06	8.97e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	9.07e-06	8.48e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.98e-06	8.4e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—AKT1—malignant glioma	8.69e-06	8.13e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.84e-06	7.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—malignant glioma	7.72e-06	7.23e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAT—malignant glioma	7.52e-06	7.03e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOR1—malignant glioma	7.1e-06	6.64e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CAV1—malignant glioma	5.79e-06	5.41e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.53e-06	5.17e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CG—malignant glioma	5.27e-06	4.93e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—malignant glioma	5.09e-06	4.76e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CD—malignant glioma	4.63e-06	4.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CB—malignant glioma	4.04e-06	3.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—malignant glioma	4e-06	3.74e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—malignant glioma	3.49e-06	3.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—malignant glioma	2.46e-06	2.3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—AKT1—malignant glioma	2.01e-06	1.88e-05	CbGpPWpGaD
